Skip to main content

Advertisement

SpringerLink
Log in

Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications

  • Viewpoint
  • Published:

From Nature Clinical Practice Endocrinology & Metabolism

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kimura ET et al. (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63: 1454–1457

    CAS  PubMed  Google Scholar 

  2. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12: 245–262

    Article  CAS  Google Scholar 

  3. Ciampi R et al. (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115: 94–101

    Article  CAS  Google Scholar 

  4. Knauf JA et al. (2005) Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 65: 4238–4245

    Article  CAS  Google Scholar 

  5. Giordano TJ et al. (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24: 6646–6656

    Article  CAS  Google Scholar 

  6. Castro P et al. (2006) PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91: 213–220

    Article  CAS  Google Scholar 

  7. Xing M et al. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373–6379

    Article  CAS  Google Scholar 

  8. Vasko V et al. (2005) High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab 90: 5265–5269

    Article  CAS  Google Scholar 

  9. Nikiforova MN et al. (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88: 5399–5404

    Article  CAS  Google Scholar 

  10. Ouyang B et al. Inhibitors of raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res, in press

Download references

Author information

Authors and Affiliations

  1. visiting post-doctoral fellow (from Groupe Hospitalier Cochin, Paris, France), University of Cincinnati College of Medicine, Cincinnati, OH, USA

    Lionel Groussin

  2. Professor of Medicine in the Division of Endocrinology and Metabolism, University of Cincinnati College of Medicine, Cincinnati, OH, USA

    James A Fagin

Authors
  1. Lionel Groussin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James A Fagin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James A Fagin.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Groussin, L., Fagin, J. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat Rev Endocrinol 2, 180–181 (2006). https://doi.org/10.1038/ncpendmet0161

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0161

  • Springer Nature Limited

Search

Navigation